MRD Monitoring in Lung Cancer After Resection
Recruiting · NCT04976296 · Observational (researchers observe without assigning treatment) · Lead sponsor: Guangdong Provincial People's Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients who underwent complete resection. Preoperative blood sample, tumor tissue and dynamic postoperative blood samples are collected continuously for MRD detection. This study aim to explore the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.
Who can take part
Inclusion criteria
- Diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable (stage I-IIIA) disease.
- Complete resection
- Age ≥18 years at the time of screening
- Capable of giving signed informed consent
Exclusion criteria
- Mixed small cell and NSCLC histology
- Rx, R1 or R2 resection
- History of other malignant tumors within 5 years
Where it is running
1 location listed.
- Guangdong Lung Cancer Institute & Guangdong Provincial People's Hospital - Guangzhou, Guangdong, China